<DOC>
	<DOCNO>NCT01549314</DOCNO>
	<brief_summary>The purpose study determine whether ivacaftor , recently FDA-approved CFTR potentiator , improve bone micro-architecture strength patient cystic fibrosis least one G551D CFTR mutation .</brief_summary>
	<brief_title>Cystic Fibrosis Related Bone Disease : Role CFTR</brief_title>
	<detailed_description>Ivacaftor , CFTR potentiator , recently FDA approve treatment cystic fibrosis patient least one G551D CFTR mutation . Given possible role CFTR bone , hypothesize medication may also improve bone health CF patient . The purpose study test hypothesis use high resolution peripheral quantitative compute tomography , research tool measure bone micro-architecture volumetric bone density ability detect small change bone might otherwise miss standard bone image technique bone density testing .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<criteria>COHORT 1 Age 6 75 year old Established diagnosis CF least one abnormal G551DCFTR allele Eligibility intent start treatment ivacaftor start treatment ivacaftor within previous 6 month Psychiatric mental incapacity would preclude subject assent study participation Current pregnancy History organ transplantation History Burkholderia dolosa infection COHORT 2 : Subjects group gender , age race match subject Cohort 1 within two year . Pubertal subject match Tanner stage . Age 6 75 year old Established diagnosis CF Psychiatric mental incapacity would preclude subject assent study participation Current pregnancy History organ transplantation History Burkholderia dolosa infection COHORT 3 : Subjects group gender , age race match subject Cohort 2 within two year . Pubertal subject match Tanner stage . Inclusion criterion : Age 6 75 year old Clinically stable , deem able complete screening , baseline , schedule study visit . Exclusion criterion : History significant cardiac , renal , pulmonary , hepatic , malignant disease , current alcohol illicit drug abuse , major psychiatric disorder Current diagnose know affect bone metabolism , include cystic fibrosis , osteoporosis , amenorrhea &gt; 3 month ( menstruate woman take oral contraceptive IUD ) , hyperthyroidism , diabetes , hyperparathyroidism , Paget 's disease , kidney stone , chronic inflammatory disease , malabsorptive disorder , malnutrition , prolonged immobility , skeletal dysplasias History nondigital fracture previous 6 month , history one pathologic fracture , great four total lifetime nondigital fracture Cumulative lifetime use oral glucocorticoid great 2 month Current prior use medication know affect bone metabolism include hormone replacement therapy , antiestrogens , bisphosphonates , calcitonin , fluoride , lithium , suppressive dos levothyroxine , anticonvulsant . Pregnancy BMI le 18.5 great 30 kg/m2 subject 18 year old , BMI le 5th great 95th percentile subject age 18 year . Any medical psychiatric condition situation would compromise subject safety , informed consent/assent , treatment compliance , followup measurement , data quality</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Cystic fibrosis relate bone disease</keyword>
	<keyword>Cystic fibrosis</keyword>
	<keyword>Ivacaftor</keyword>
</DOC>